Stock Movers: US Steel, BYD, Bristol Myers (Podcast)

US Steel (X) is trading lower after President Trump announced plans to increase steel and aluminum tariffs to 50%, while competitor Cleveland Cliffs (CLF) is moving higher on the same news; BYD (BYDDY) shares declined amid concerns that its price cuts are drawing government scrutiny; Bristol Myers (BMY) is up after agreeing to pay BioNTech SE up to $11.1 billion to license a next-generation cancer drug.

Analysis

The US steel sector is experiencing divergent reactions to President Trump's proposal to increase steel and aluminum tariffs to 50% from 25%. United States Steel Corporation (X) shares traded weaker following the announcement, despite Trump's visit to a US Steel plant where he championed an expected deal with Nippon Steel Corp. and promised worker bonuses and a $2.2 billion investment to increase steel production, contingent on the firm remaining US-owned. Conversely, competitor Cleveland-Cliffs Inc. (CLF) saw its shares rise, suggesting investors perceive it as a prime beneficiary of heightened protectionist measures. In the electric vehicle market, BYD (BYDDY) shares declined due to concerns that its aggressive price-cutting strategy is attracting Chinese government scrutiny and is viewed as potentially unsustainable for the industry, with authorities and associations worried about "vicious competition" impacting profit margins and product quality. Meanwhile, Bristol Myers Squibb (BMY) shares moved higher, along with the broader pharmaceutical sector, reflecting positive investor sentiment after the company agreed to a significant licensing deal with BioNTech SE (BNTX) for a next-generation cancer drug. This deal involves up to $11.1 billion in payments, including $1.5 billion upfront and $2 billion in installments through 2028, and also represents a substantial return for BioNTech on its earlier acquisition of the compound.

Key Decisions for Investors

• Investors should closely monitor developments around proposed US steel tariffs and the US Steel-Nippon Steel deal, as these factors are creating divergent opportunities and risks for companies like US Steel (X) and Cleveland-Cliffs (CLF).
• Exposure to Chinese EV manufacturers such as BYD (BYDDY) warrants caution due to potential government intervention against aggressive pricing strategies, which could impact profitability and overall market dynamics in the sector.
• The significant licensing deal by Bristol Myers (BMY) underscores the strategic importance of pipeline development in pharmaceuticals; investors might consider companies with robust R&D and valuable intellectual property, as highlighted by BioNTech's (BNTX) successful asset monetization.